Investigational drug · Phase 2
SNS-101
Also called: anti-VISTA
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "SNS-101"
First trial start
2023
May 31, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SNS-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor, Adult
- Advanced Solid Tumor
- Head and Neck Cancer
- Breast Cancer
- Colon Cancer
- Pancreatic Cancer
- Gastric Cancer
- Esophageal Cancer
- Prostate Cancer
- Uterine Cancer
Approved drugs for the same conditions: Breast cancer · Prostate cancer · Pancreatic cancer · Stomach and esophageal cancer · Head and neck cancer · Oncology · Kidney and urology · Gastroenterology and liver · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "SNS-101" as an intervention, largest first.
Sensei Biotherapeutics, Inc.Industry
NCT05864144 · 98 participants · Start May 31, 2023 · Primary completion Jun 2, 2026
Drug: SNS-101 (anti-VISTA); Cemiplimab · For: Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer and 19 more
Sites: Los Angeles, California; Aurora, Colorado; Louisville, Kentucky · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Balancing the Dual Mechanisms of Anti-VISTA mAbs for Antitumor Activity: CD8+ T-cell Responses and Fc-Dependent Depletion of VISTA-Expressing Immune Cells.
He M, Cao T, Wang K, et al. · Mol Cancer Ther 2026
- VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer.
Huo C, Zhao X, Ye D, et al. · Cancer Immunol Res 2026
- Roles of V-domain Ig suppressor of T-cell activation-mediated immunoregulation in tumor immune escape (Review).
Chen Y, Wang S, Yang B, et al. · Oncol Lett 2026
- Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.
Mahadevan KK, Maldonado AS, Li B, et al. · Nat Commun 2026
- Combined targeting of VISTA and sorafenib activates T cell-mediated anti-tumor immunity via the NF-κB/TNF axis in hepatocellular carcinoma.
Wang J, Zeng X, Liu W, et al. · BMC Med 2026
- First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours.
Gomez-Roca C, Champiat S, Danlos FX, et al. · BMJ Oncol 2026
Also in development for Solid Tumor, Adult
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- CRB-701Phase 32 trials
Corbus Pharmaceuticals Inc. · Solid Tumor, Adult, Oropharyngeal Carcinoma (OPC)
- HMPL-453Phase 32 trials
Hutchmed · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials
A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.